Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling
Sotagliflozin treatment improved left ventricular function, myocardial perfusion, and diastolic relaxation, likely through reduced nitrosative stress and myocardial fibrosis, improved nitric oxide coupling, enhanced insulin signaling, and favorable metabolic shifts. This study suggests a potential role for sotagliflozin as a cardioprotective therapy in patients with ischemic heart disease beyond current treatment strategies.
Authors
- Frank W. Sellke (ORCID: https://orcid.org/0000-0002-8886-801X)
- Kelsey Muir (ORCID: https://orcid.org/0000-0001-8768-5468)
- Dwight D. Harris (ORCID: https://orcid.org/0000-0001-8289-2740)
- M. Ruhul Abid (ORCID: https://orcid.org/0000-0003-2981-2638)
- Christopher Stone (ORCID: https://orcid.org/0000-0001-6457-2663)
- Meghamsh Kanuparthy (ORCID: https://orcid.org/0009-0005-7581-0555)
- Jad Hamze (ORCID: https://orcid.org/0009-0000-2758-8746)
- Riya Reddy (ORCID: https://orcid.org/0000-0002-2033-6279)
Institutions
- Brown University (US)
- Rhode Island Hospital (US)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1161/atvbaha.125.323916
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00